In CLL, XPO1 expression is elevated in malignant B cells relative to their normal counterparts, and mutations in XPO1 have been correlated with high-risk genetic aberrations and accelerated disease progression [146]. This evidence concerns the gene XPO1 and B-cell chronic lymphocytic leukemia.